LOGIN  |  REGISTER
Recursion
Terns Pharmaceuticals

Addus HomeCare to Participate in the 2024 Jefferies Global Healthcare Conference

May 29, 2024 | Last Trade: US$101.25 0.25 0.25

FRISCO, Texas / May 29, 2024 / Business Wire / Addus HomeCare Corporation (Nasdaq: ADUS), a provider of home care services, today announced that Dirk Allison, Chairman and Chief Executive Officer, Brad Bickham, President and Chief Operating Officer, and Brian Poff, Executive Vice President and Chief Financial Officer, will participate in the 2024 Jefferies Global Healthcare Conference, which takes place on June 4 - 6, 2024, in New York City.

In connection with the conference, there will be a live broadcast and replay of the Company’s presentation available under the Investor Relations section of the Company’s website, www.addus.com, starting at 12:30 p.m. Eastern Time / 11:30 a.m. Central Time on Wednesday, June 5, 2024. An online replay will also be available on the Company’s website for one month, beginning approximately one hour following the conclusion of the live broadcast.

About Addus HomeCare

Addus HomeCare is a provider of home care services that primarily include personal care services that assist with activities of daily living, as well as hospice and home health services. Addus HomeCare’s consumers are primarily persons who, without these services, are at risk of hospitalization or institutionalization, such as the elderly, chronically ill and disabled. Addus HomeCare’s payor clients include federal, state, and local governmental agencies, managed care organizations, commercial insurers, and private individuals. Addus HomeCare currently provides home care services to over 49,000 consumers through 214 locations across 22 states. For more information, please visit www.addus.com.

Astria Therapeutics

Stock Quote

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

Featured Stock

Terns Pharmaceuticals

Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page